On Invalid Date, Biofrontera (NASDAQ: BFRI) reported Q4 2022 earnings per share (EPS) of -$0.14, up 89.86% year over year. Total Biofrontera earnings for the quarter were -$2.79 million. In the same quarter last year, Biofrontera's earnings per share (EPS) was -$1.38.
On Invalid Date, Biofrontera (NASDAQ: BFRI) reported Q4 2022 revenue of $10.14 million up 10.65% year over year. In the same quarter last year, Biofrontera's revenue was $9.17 million.
What was BFRI's revenue growth in the past year?
As of Q1 2023, Biofrontera's revenue has grown 18.98% year over year. This is 229.77 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 248.75%. Biofrontera's revenue in the past year totalled $28.67 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.